Additional file 1 of Combined effect of adiposity and elevated inflammation on incident type 2 diabetes: a prospective cohort study
Creators: name: Wu, Dan
name: Lan, Yulong
name: Chen, Shuohua
name: Ding, Xiong
name: Chen, Guanzhi
name: Wu, Chutao
name: Balmer, Lois
name: Xu, Wencan
name: Wu, Shouling
name: Wang, Wei
Publisher: name: figshare
Year: 2024
Subjects: subject: Biochemistry
subject: Genetics
subject: FOS: Biological sciences
subject: Biotechnology
subject: Chemical Sciences not elsewhere classified
subject: Immunology
subject: FOS: Clinical medicine
subject: Biological Sciences not elsewhere classified

description: Additional file1: Figure S1. Flowchart of the study participants. Table S1. Baseline characteristics of raw data. Table S2. HsCRP-associated type 2 diabetes risks in the entire cohort (14278/82172). Table S3. BMI(China)-associated risk of incident type 2 diabetes in the entire cohort and stratified by hsCRP strata (&lt;2, ≥2 mg/L). Table S4. Fatty liver-associated risk of incident type 2 diabetes in the entire cohort and stratified by hsCRP strata (&lt;2, ≥2 mg/L). Table S5. The risks of incident type 2 diabetes upon adiposity indices with adjustment for the product term of multiplicative interaction with hsCRP (&lt;2, ≥2 mg/L). Table S6. The risks of incident type 2 diabetes upon co-exposure to increased BMI and hsCRP levels. Table S7. The risks of incident type 2 diabetes upon co-exposure to central obesity (waist circumference) and elevated hsCRP levels. Table S8. The risks of incident type 2 diabetes upon co-exposure to fatty liver and elevated hsCRP levels. Table S9. HsCRP-associated risk of incident type 2 diabetes in the entire cohort and stratified by hsCRP strata (&lt;1, 1~3, ≥3mg/L). Table S10. HsCRP-associated risk of incident type 2 diabetes in the entire cohort and stratified by hsCRP strata (&lt;3, ≥3mg/L). Table S11. BMI-associated risk of incident type 2 diabetes in the entire cohort and stratified by hsCRP strata (&lt;3, ≥3 mg/L). Table S12. Additive interaction of overweight/obesity and hsCRP≥3 mg/L. Table S13. The risks of incident type 2 diabetes upon co-exposure to BMI and hsCRP levels (&lt;3, ≥3 mg/L). Table S14. Sensitivity analysis of the risks of incident type 2 diabetes upon co-exposure to BMI and hsCRP levels by excluding CVD (13685/79714). Table S15. Additive interaction of overweight/obesity and hsCRP≥2 mg/L by excluding individuals with pre-existing CVD (13685/79714). Table S16. Sensitivity analysis of risks of incident type 2 diabetes upon co-exposure to BMI and hsCRP levels by excluding suspected infection (13646/78992). Table S17. Additive interaction of overweight/obesity and hsCRP≥2 mg/L by excluding individuals with suspected infection (13646/78992). Table S18. Reverse analysis of the risks of incident type 2 diabetes upon co-exposure to BMI and hsCRP levels (&lt;2, ≥2 mg/L) (10601/78495). Table S19. Additive interaction of overweight/obesity and hsCRP≥2 mg/L in the reverse analysis (10601/78495). Table S20. The risks of incident type 2 diabetes upon co-exposure to BMI and hsCRP levels (&lt;2, ≥2 mg/L) on raw data. Table S21. Additive interaction of overweight/obesity and hsCRP≥2 mg/L on raw data.